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Abstract
Growth/differentiation factor 5 (GDF5) is a neurotrophic factor that promotes the survival of midbrain dopaminergic neurons in vitro and in vivo
and as such is potentially useful in the treatment of Parkinson’s disease (PD). This study shows that a continuous supply of GDF5, produced by
transplanted GDF5-overexpressing CHO cells in vivo, has neuroprotective and neurorestorative effects on midbrain dopaminergic neurons fol-
lowing 6-hydroxydopamine (6-OHDA)-induced lesions of the adult rat nigrostriatal pathway. It also increases the survival and improves the
function of transplanted embryonic dopaminergic neurons in the 6-OHDA-lesioned rat model of PD. This study provides the first proof-of-princi-
ple that sustained delivery of GDF5 in vivo may be useful in the treatment of PD.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative disease
characterized by motor symptoms that are caused by the progres-
sive degeneration of dopaminergic neurons projecting from the sub-
stantia nigra (SN) to the striatum. Currently, the mainstay therapy of
PD involves exogenous L-dopa or dopamine receptor agonists, but
these treatments become less effective as the disease progresses
(for review, see [1]). Alternative experimental treatment strategies
include the use of neuroprotective agents to rescue the remaining
dopaminergic neurons, and the replacement of the lost dopaminergic
neurons by transplantation of embryonic midbrain [ventral mesen-
cephalon (VM)] tissue ectopically in the striatum. While many stud-
ies have shown that VM transplants can survive, integrate and
improve motor function in patients (for reviews see [1–6]), signifi-
cant obstacles need to be overcome, before this approach is widely
used for PD therapy (for recent reviews, see [7, 8]). In addition to
the need for standardization and optimization of surgical methodol-
ogy and patient selection, there is a critical problem regarding the
survival of the transplanted cells. Only 5–10% of the dopaminergic
neurons survive the grafting procedure [4, 9], and several agents are
under investigation for their potential to improve dopaminergic neu-
ronal survival after transplantation (for reviews, see [10–13]). Neuro-
trophic factors are proteins that play important roles to support
specific neuronal populations in the developing brain, and also have
protective actions on some populations of mature neurons. Neuro-
trophic factors that have such effects on dopaminergic neurons are
being studied by many groups with regards to their potential to
improve the survival of transplanted dopaminergic neurons, as well
as to prevent the ongoing degeneration of nigrostriatal neurons in
the parkinsonian brain (for reviews see [11, 14, 15]).
Growth/differentiation factor 5 (GDF5) is a member of the trans-
forming growth factor (TGF)-b superfamily of proteins [16]. In the
embryonic rat midbrain, GDF5 expression correlates temporally with
the differentiation of dopaminergic neurons, peaking at embryonic
day (E) 13-14 [17], around the time when these cells are undergoing
the final stages of their division and maturation [18, 19]. GDF5 treat-
ment increases the survival of dopaminergic neurons in cultures of
embryonic rat VM, and improves their morphological development
[20–22]. Furthermore, GDF5 treatment attenuates the dopaminergic
neurotoxicity induced by either the neurotoxin N-methyl pyridinium
ion (MPP+) [23] or free radical donors [24] in cultures of E14 rat VM.
In vivo, intracerebral administration of GDF5 confers neuroprotective
and neurorestorative effects on the adult rat nigrostriatal pathway in
6-hydroxydopamine (6-OHDA)-lesioned adult rat models of PD
[25–27]. Furthermore, GDF5 treatment increases the survival of
embryonic rat dopaminergic neurons after intrastriatal transplantation
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in 6-OHDA-lesioned adult rats [21, 28]. However, the effects of long-
term exposure to GDF5 on E14 VM transplants or on the host adult
rat brain have not been examined. As GDF5 has been proposed as a
candidate neurotrophic factor for PD treatment, information on its
sustained delivery is necessary. This study set out to examine the
effects of GDF5 production by a GDF5-overexpressing CHO cell line,
after intrastriatal implantation and after co-implantation with E14 rat
VM grafts in 6-OHDA-lesioned adult rat models of PD. This GDF5 pro-
duction in vivo was found to have neuroprotective and neurorestor-
ative effects on the host nigrostriatal system and to improve the
survival and morphology of the co-transplanted VM dopaminergic
neurons. These data corroborate previous studies showing neuropro-
tective and restorative effects of GDF5 in adult rat models for PD, and
support the future development of appropriate delivery systems to
achieve long-term and targeted delivery of this neurotrophic factor to
the damaged nigrostriatal pathway in this disease.
Materials and methods
Cell culture and western blotting
A CHO cell line (‘GDF5-CHO’) stably transfected with the human GDF5
gene, and a CHO cell line (‘mock-CHO’) stably transfected with an
empty plasmid were kind gifts from Biopharm GmbH, Heidelberg, Ger-
many. The GDF5-CHO cell line was invented and subsequently patented
[European patent: EP 0 866 125 A1] by Hoechst Marion Roussel, Ltd.,
Tokyo 107-8465, Japan. This involved the ligation of a DNA fragment
containing the human GDF5 gene into a pAB stop vector; the resulting
vector was designated pMS99. Ten micrograms of pMS99 and 2 lg of
pSV0Adhfr were dissolved in 1 ml of 25 mM HEPES, 140 mM NaCl,
0.75 mM Na2HPO4, then mixed with 50 ll of 2.5 M CaCl2. This mixture
was applied to CHO cells for 30 min. The cells were cultured in MEMa+
(MEM-alpha containing ribo- and deoxyribonucleosides) containing 10%
foetal bovine serum (FBS) for 4–6 h at 37°C. The cells were treated
with 10% glycerol in MEMa+ containing 10% FBS for 3 min and then
cultured for 2 days in MEMa+ containing 10% FBS. The cells were
placed in MEMa without ribo- and deoxyribonucleosides (MEMa) con-
taining 10% dialysed FBS for selection of the transformants. Clones
which produced high levels of GDF5 were selected stepwise in increas-
ing concentrations of methotrexate to amplify the GDF5 gene in accor-
dance with the pSV0Adhfr. The CHO cell line with the highest GDF5
production (MC-2) was selected and further cultured in MEM-a with
10% foetal calf serum (FCS), 2 mM L-glutamine, 400 nM methotrexate,
100 U/ml penicillin, 100 lg/ml streptomycin (all from Sigma-Aldrich,
Arklow, Wicklow, Ireland) until confluent. For GDF5 production, the cells
were cultured in DMEM/Ham’s F12, supplemented with 10 KIU aproti-
nin, 1 mM sodium butyrate, 6.7 ng/ml sodium selenate, 5.5 lg/ml
transferrin, 2 lg/ml ethanolamine, 9 lg/ml insulin, 100 U/ml penicillin,
100 lg/ml streptomycin (all from Sigma-Aldrich). Every day, two-thirds
of this serum-free medium were harvested and stored at 20°C. Wes-
tern blotting was performed on conditioned medium samples and CHO
cell lysates, as previously described [17]. Cell lysates were prepared by
incubation of cells in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl,
10% glycerol, 1% Triton X-100, 1 mM EDTA, 0.32 M sucrose, 100 lg/
ml PMSF, 1 lg/ml bacitracin, 1 lg/ml pepstatin A, 1 lg/ml aprotinin,
1 lg/ml leupeptin and 1 lg/ml antipain) on ice for 1 h. Insoluble debris
was removed by centrifugation at 10,000 9 g for 10 min at 4°C. Pro-
tein concentrations were determined using a Bradford assay with bovine
serum albumin (BSA), as a standard. Sample extracts containing 30 lg
of protein or 15 ll of conditioned medium were diluted 1:1 in a reduc-
ing sample buffer [7 M urea, 0.1% sodiumphosphate, 1% sodium dode-
cyl sulphate (SDS), 0.01% bromophenol blue, 100 mM dithiothreitol],
and samples were separated on a 12% SDS-polyacrylamide gel and
blotted to PVDF membranes. Recombinant human GDF5 (50 ng) was
run as a positive control. Blots were incubated in either of the primary
antibodies, MP-52 (which recognizes monomeric GDF5) or aMP-5
(which recognizes dimeric GDF5; both kindly provided by Biopharm
GmbH), for 12–16 h in 1% BSA dissolved in 10 mM PBS containing
0.1% Tween20 (PBS-T). Following three washes for 10 min in PBS-T,
blots were incubated in horseradish peroxidase (HRP)-labelled anti-rab-
bit or anti-mouse IgG (1:2000; Promega, Southampton, UK). Mem-
branes were rinsed three times for 10 min with PBS-T and developed
with ECL Plus (GE Healthcare Bio-Sciences, Buckinghamshire, UK).
Cultures of E14 rat VM were prepared as previously described [20]. A
total volume of 4 ml of conditioned medium harvested from GDF5-CHO
cells at 2 days in vitro (DIV) was concentrated to 500 ll, with molecular
weight cut-off filters (Millipore, Watford, UK). The concentrated medium
samples were added directly to the medium of E14 rat VM cultures at a
final dilution of 1:10. Control cultures received medium from mock-CHO
cells. The cultures of E14 rat VM were grown for a further 3 DIV before
being fixed and processed for immunocytochemistry for tyrosine hydroxy-
lase (TH; 1:300; rabbit polyclonal; Millipore) or b-III tubulin (1:300, mouse
monoclonal; Promega), visualized with HRP-linked secondary antibodies
and counter-stained with DAPI (1:5000; Sigma-Aldrich).
Lesion surgery and behavioural testing
Female Sprague–Dawley rats, approximately 3 months old and weighing
200–270 g, were used for all experiments (Biological Services Unit, UCC).
In each experiment, there were five rats in each treatment group. Each rat
received either a complete unilateral lesion of the left medial forebrain
bundle (MFB) or left striatum, as previously described [25, 26]. Briefly,
rats were anaesthetized with a mixture of ketamine (80 mg/kg, i.p.) and
xylazine (5 mg/kg, i.p.). Surgery was carried out with a Kopf® stereotaxic
frame (Tajunga, CA, USA) with the incisor bar set at 5.0 mm above the in-
teraural line and the co-ordinates taken from bregma and dura [29]. For
MFB lesions, 6-OHDA (8 lg as free base in 4 ll 0.9% saline with 0.1%
ascorbic acid) was injected at the following co-ordinates: AP: 2.2, LV:
+1.5, DV: 7.9. For striatal lesions, 6-OHDA (20 lg as free base in 3 ll
0.9% saline with 0.1% ascorbic acid) was injected at the following co-
ordinates: AP: +1.0, LV: +3.0, DV: 5.0. Following surgery, animals were
housed singly in an environmentally controlled room with free access to
food and water. At various time-points, rotational behaviour was assessed
after injection of (+)-amphetamine sulphate (5 mg/kg, i.p., Sigma-
Aldrich). Rotations were recorded over 60 min beginning 5 min after
amphetamine injection and are expressed as the mean of full body ipsiver-
sive turns minus contraversive turns.
Transplantation and immunosuppression
For the transplant experiments, either mock-CHO or GDF5-CHO cells
were stereotaxically injected into either the striatum at the same time as
6-OHDA injection into the ipsilateral MFB or into the striatum or SN at
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7 days after intrastriatal 6-OHDA injection (5 9 105 cells divided
equally between three sites). The following co-ordinates were used
(incisor bar at +5.0 mm): SN: AP 3.0, ML +2.5, DV 8.5, 7.5,
6.5; striatum: AP +1.0, LV +3.0, DV 5.0, 4.0, 3.0. For co-trans-
plantation experiments, a suspension of 5 9 105 E14 VM cells was pre-
pared as previously described [28], mixed with 5 9 105 mock-CHO or
GDF5-CHO cells and transplanted stereotaxically into the left striatum at
7 days after 6-OHDA injection into the ipsilateral MFB, divided equally
between three sites at the co-ordinates described above. For GDF5-trea-
ted grafts, 50 lg rhGDF5 (a gift from Biopharm GmbH) was mixed with
the E14 cell suspension prior to transplantation. For the ‘sham graft’
group, an equivalent volume of saline was injected using identical surgi-
cal procedures and co-ordinates as used for the grafting groups. For
immunosuppression, rats (where indicated) received oral cyclosporin A
(Cy-A-Neoral®) at a dose of 5 mg/kg/day for 5 days prior to transplan-
tation and daily until killed.
Immunohistochemistry
All animals were transcardially perfused with 4% paraformaldehyde
(Sigma-Aldrich) in PBS, the brains were post-fixed by immersion, 4%
paraformaldehyde for 24 h, then cryopreserved in 30% sucrose. Coronal
10 lm sections were collected through the entire region of the striatum
with a cryostat (Leica M1900, Laboratory Instruments and Supplies, Ash-
bourne, Ireland) and processed for immunohistochemistry as previously
described [25], using the following primary antibodies: GDF5 (aMP-5;
1:200, Biopharm), TH (1:1000, Millipore), MHC I (1:400; Serotec, Serotec
Ltd, Kidlington, Oxford, UK), MHC II (1:400; Serotec), CD 4 (1:400; Sero-
tec), CD 8 (1:400; Serotec), ED 1 (1:400; Serotec), IgM (1:200; Sigma-
Aldrich) and visualized using HRP-linked secondary antibodies.
Data analysis
For analysis of the cellular phenotypic composition of primary cultures
following treatment with conditioned medium, four random fields were
analysed per culture well. Total cell number and number of immunoreac-
tive cells per field were quantified. Data are presented as mean ± S.E.M.
of 12 wells from three independent experiments. Statistical evaluation
was performed using Student’s t-test, with significance set at P < 0.05.
Quantification of dopaminergic neurons in the host midbrain and in the
grafts was performed with the unbiased Physical Paired Dissector and
Cavalieri stereological methods [30], as described previously [21]. In
brief, pairs of sections from each of three levels through the midbrain (AP
4.8, 5.6 and 6.4 relative to bregma; [31]) were examined under 209
objective with an Olympus-X70 fluorescence microscope. Representative
fields (three per SN, per hemisphere) were photographed and cells were
counted by a blinded observer. The unbiased Physical Paired Dissector
method was used to measure the numerical density of TH-immunoposi-
tive neurons in each SN [30]. For the MFB and striatal lesion studies, data
are presented as the number of TH-immunopositive neurons in each
lesioned SN as a percentage of that in the intact SN of the same animal.
For the graft study, data are presented as the number of TH-immunoposi-
tive neurons in the grafted striatum post-mortem as a percentage of the
estimated number of dopaminergic neurons in the original graft (assumed
to be 10% of the total number of grafted cells).
Quantification of the immune response in the host striatum was per-
formed with a rating scale, as previously described [32]. Statistical eval-
uation of normally distributed data (parametric data) was carried out
with univariate (ANOVA), and multivariate analysis of variance (MANOVA)
with post-hoc Tukey’s testing. Significance was set at P < 0.05.
Results
Conditioned medium from a GDF5-
overexpressing CHO cell line increases the
number of dopaminergic neurons in cultures of
E14 rat VM
To achieve long-term expression of GDF5 in vitro and in vivo, a CHO
cell line that had been stably transfected with the human GDF5 gene
(GDF5-CHO) was used. Firstly, this cell line was characterized in vi-
tro. GDF5-CHO cells were cultured for 3 DIV before being fixed and
processed for immunocytochemistry. Confocal microscopy showed
that these cells displayed abundant intracellular immunoreactivity for
GDF5, which was predominantly localized in vesicles (Fig. 1A). To
confirm that these cells produced mature GDF5 protein, Western
blotting was performed on cell lysates and on conditioned medium
from these cultures. In cell lysates, a number of high molecular
weight bands were detected, one of which had a molecular weight of
55 kD (Fig. 1B), which corresponds to that of the monomeric form
of the GDF5 precursor protein. The other high molecular weight
bands correspond to various processed (dimeric) forms of the pre-
cursor protein. Mature GDF5 was not detected intracellularly
(Fig. 1B). To determine whether these cells secreted mature GDF5,
conditioned medium samples from mock-CHO and GDF5-CHO cells
were examined under reducing conditions. Mock-transfected cells
did not secrete GDF5 (Fig. 1C), whereas GDF5-CHO cells secreted
both GDF5 precursor proteins and mature (monomeric; 15 kD)
GDF5 into the medium for at least 15 DIV (Fig. 1C). These cells con-
tinued to secrete GDF5 precursor proteins after 21 DIV, but did not
secrete mature GDF5 protein at this time-point (Fig. 1C). To confirm
the presence of biologically active (dimeric; 25 kD) GDF5, Western
blotting was performed under non-reducing conditions using an anti-
body (aMP5) that recognizes the dimeric form of GDF5. This showed
that the GDF5-CHO cells secreted mature GDF5 for up to 15 DIV,
whereas mock-CHO cells did not produce dimeric GDF5 at any point
(Fig. 1D).
To examine the effects of GDF5 secreted from the CHO cell line on
dopaminergic neurons in vitro, E14 rat VM cultures were treated with
conditioned medium from either GDF5-CHO or mock-CHO cells for 3
DIV. A pilot study on E14 rat VM cultures had demonstrated that
mock-CHO cell conditioned medium had no effect on the number of
TH-immunopositive cells, b-III tubulin-positive cells or total number
of cells, compared with control medium. Immunocytochemical analy-
sis showed that treatment with the GDF5-CHO conditioned medium
resulted in a twofold increase in the numbers of dopaminergic neu-
rons per field after 3 DIV, compared with treatment with the mock-
CHO conditioned medium (Fig. 1E; P < 0.05). Treatment with GDF5-
CHO conditioned medium did not have any significant effect on the
total numbers of neurons per field (Fig. 1F) or the total number of
ª 2012 The Authors 2453
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cells per field (Fig. 1G), compared with those in cultures treated with
mock-CHO conditioned medium.
Characterization of the host immune responses
to CHO cell xenografts and to E14 rat VM
allografts in the adult rat striatum
Prior to characterizing the functional effects of intrastriatal implanta-
tion of GDF5-CHO cell xenografts in PD models, the host immune
response to these xenografts was examined in unlesioned adult rats
and compared with that response to allografts of E14 rat VM. Further-
more, the effect of oral administration of CyA on the host response to
CHO cell grafts was characterized. Suspensions of 5 9 105 E14 rat
VM cells or 5 9 105 CHO cells were implanted into the striata of adult
rats. A third group of rats received intrastriatal grafts of CHO cells as
well as treatment with oral CyA (5 mg/kg/day) for the previous 5 days
and every day thereafter until being killed. At 5, 10, 21 and 42 days
post-lesion, groups of animals were perfused and processed for
immunocytochemistry. There was a robust host immune response,
as evidenced by strong immunoreactivity for CD 4, CD 8, MHC I,
MHC II, IgM and ED 1 around the graft site in the striatum of each rat
that had received a CHO xenograft without CyA (Fig. 1A–D). A weaker
immmue response was observed in the striata of rats that had
received CyA treatment as well as a CHO xenograft, and in those that
had received an E14 VM allograft. This immunoreactivity was quanti-
fied using a rating scale from 0 (no immunostaining) to 4 (very dense
immunostaining in and around the graft) [32]. In general, the xeno-
grafts elicited a more robust host immune response than the allo-
grafts, but oral administration of CyA significantly reduced the extent
of this response to equal or lower levels as that elicited by the allo-
grafts (Fig. 2E–J).
GDF5-overexpressing CHO cells secrete GDF
in vivo after implantation into the adult rat striatum
To establish whether grafts of GDF5-CHO cells could produce GDF5
protein in vivo, 5 9 105 mock-CHO or GDF5-CHO cells were
implanted into the striata of adult rats and the brains of these animals
were processed for GDF5 immunohistochemistry at 1, 3, 5 and
7 days post-transplantation. Strong expression of GDF5 was seen in
the striatum of each rat that had received a GDF5-CHO graft, at all
time-points examined (Fig. 2L and N). No GDF5 immunoreactivity
was detected in striata of rats that had received mock-CHO cells
(Fig. 2K and M). The immunostaining was maximal in the region of
the implant, with very little staining in other areas.
Transplantation of GDF5-overexpressing CHO
cells confers neuroprotective and
neurorestorative effects on adult rat midbrain
dopaminergic neurons
To investigate whether the GDF5-CHO cells could ameliorate the
effects of a 6-OHDA lesion of the adult rat MFB, groups of rats
received oral CyA for 5 days prior to receiving an injection of either
5 9 105 mock-CHO cells or 5 9 105 GDF5-CHO cells into the left
striatum, in addition to a 6-OHDA injection into the left MFB (Fig. 3A).
At 7 and 21 days after lesion surgery, animals that had received only
a 6-OHDA lesion displayed rotation rates of more than eight ipsiver-
sive turns per minute, which indicates almost complete ablation of
the ipsilateral nigrostriatal pathway [33]. Those animals that had
received a transplant of mock-CHO cells had rotational rates that were
A
C
D
B E
F
G
Fig. 1 Characterization of GDF5 expression and secretion by the GDF5-
CHO cell line in vitro. (A) Representative photomicrograph of a single
GDF5-CHO cell grown for 3 DIV, immunocytochemically stained for
GDF5. Scale bar = 10 lm. (B) Western blot detection (using MP52 anti-
body) of high molecular weight GDF5 precursor proteins in a GDF5-
CHO cell extract after 15 DIV. (C) Western blot detection (run under
reducing conditions, using MP52 antibody) of GDF5 monomeric pro-
teins in conditioned medium from mock-CHO and GDF5-CHO cell cul-
tures after 1, 3, 5, 10, 15, and 21 DIV, as indicated. (D) Western blot
detection (run under non-reducing conditions, using aMP5 antibody) of
GDF5 dimeric proteins in conditioned medium from mock-CHO and
GDF5-CHO cell cultures after 1, 3, 5, 10, 15, and 21 DIV, as indicated.
rhGDF5 was run as a positive control in both (C) and (D). Graphical
representation of the number of (E) dopaminergic (TH-positive) neu-
rons, (F) total (b-III tubulin-positive) neurons and (G) total cells per
field in E14 rat VM cultures treated with conditioned medium from
mock-CHO or GDF5-CHO cells for 3 DIV. Data are shown as
mean ± SEM (*P < 0.05 compared with mock-CHO cell group; Stu-
dent’s t-test; n = 3 experiments).
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not different from animals that had received a 6-OHDA lesion only,
whereas those that had received a graft of GDF5-CHO cells displayed
significantly lower amphetamine-induced rotational rates than the
lesion-only and mock-CHO cell groups (P < 0.001; Fig. 3B). Immu-
nohistochemical analysis showed that those animals that had
received a graft of GDF5-CHO cells had significantly higher numbers
of dopaminergic neurons in the left SN (expressed as a percentage of
those in the right SN) at 4 weeks post-lesion, when compared with
lesion-only and mock-CHO cell groups (P < 0.001; Fig. 3C).
A further study used the intrastriatal 6-OHDA lesion model to
determine whether GDF5-CHO cells transplanted to the striatum or
SN at 1 week after the lesion could affect the ongoing degeneration of
the nigrostriatal pathway (Fig. 3D). Animals received oral CyA for
5 days prior to receiving an injection of 6-OHDA into the left striatum.
At 1 week after surgery, these animals received a graft of 5 9 105
mock-CHO cells or 5 9 105 GDF5-CHO cells into the left striatum or
left SN. At 28 days after lesion surgery, amphetamine-induced rota-
tional rates of at least eight turns per minute were displayed by all
rats that had received a lesion only, and those that had received
mock-CHO cells into either the SN or striatum (Fig. 3E). Those ani-
mals that had received a graft of GDF5-CHO cells into either the stria-
tum or SN displayed significantly lower rotational rates compared
with the lesion-only and mock-CHO cell (either striatum or SN)
groups (P < 0.05; Fig. 3E). Immunohistochemistry showed that the
animals that had received a graft of GDF5-CHO cells into either the
striatum or SN had significantly higher numbers of dopaminergic
neurons in the left SN at 4 weeks post-transplantation, when com-
pared with lesion-only and mock-CHO (either striatum or SN) cell
groups (P < 0.05; Fig. 3F).
Co-transplantation of GDF5-overexpressing CHO
cells increases the survival of E14 rat VM grafts
in an adult rat model of PD
The next experiment investigated whether the sustained delivery of
GDF5 in vivo could improve the survival and function of intrastriatal
grafts of E14 rat VM in adult rats that had received a 6-OHDA lesion
of the MFB (Fig. 4A). At 3 weeks after the lesion, all rats displayed
amphetamine-induced rotation rates of at least eight ipsilateral turns
per min (Fig. 4B). At 2, 3 and 6 weeks post-grafting, animals that had
received an intrastriatal graft of E14 rat VM, together with either saline
(‘graft alone’), rhGDF5 (50 lg) or 5 9 105 GDF5-CHO cells with CyA
displayed significantly lower rotation rates than at the pre-lesion test-
ing-point and than the rates displayed by rats that had received a
sham graft, or a co-graft of E14 VM and 5 9 105 GDF-CHO cells with-
A B E F
G H
I J
C D
K L
M N
Fig. 2 Characterization of GDF5 expression by the GDF5-CHO cell line in vivo and of the immune response of the host striatum to GDF5-CHO cell
transplantation. (A)–(D) Representative photomicrographs showing (A) CD 8, (B) MHC I, (C) MHC II and (D) IgM immunoreactivity at the graft sites
at 10 days after intrastriatal grafting of CHO cells. Graphical representation of the extent of the immunoreactivity to (E) CD 4, (F) CD 8, (G) MHC I,
(H) MHC II, (I) IgM and (J) Ed 1 in the adult rat striatum at 5, 10, 21 and 42 days after grafting of E14 VM cells, or CHO cells with or without oral
CyA, as indicated. (K)–(N) Representative photomicrographs showing intrastriatal transplants of mock-CHO cells and GDF5-CHO cells at 1 and
7 days post-grafting, as indicated, immunocytochemically stained for GDF5 using aMP5 antibody. Scale bar = 100 lm.
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out CyA (P < 0.001; Fig. 4B). Immunocytochemical analysis at
7 weeks post-grafting showed that there were significantly more
dopaminergic neurons in the grafts that had received rhGDF5 or had
been co-grafted with GDF5-CHO cells with CyA than in control grafts
or those that had been co-grafted with GDF-CHO cells without CyA, or
mock-CHO cells with or without CyA (P < 0.01; Fig. 4C and D).
Immunocytochemical analysis showed that the dopaminergic neurons
in E14 VM transplants that had been co-grafted with GDF5-CHO cells
and CyA were more morphologically mature than those in control
grafts. Specifically, the neurons in the co-transplants displayed longer
neurites (mean total neurite per cell 23.6 ± 7.1 lm) when compared
with those in grafts that had been implanted alone (mean total neurite
per cell 10.8 ± 3.4 lm) (see Fig. 4E).
Discussion
This study investigated the effects of long-term delivery of the neuro-
trophic factor, GDF5, on the lesioned adult rat nigrostriatal dopaminer-
gic pathway and on transplanted embryonic rat dopaminergic neurons.
It used a CHO cell line that had been modified to overexpress GDF5, to
introduce a continuous supply of this neurotrophic factor to the adult
rat brain. Thus, it built upon previous studies showing neuroprotective
[26, 27] and restorative [25] actions of GDF5 treatment on the lesioned
adult rat nigrostriatal pathway, as well as survival-promoting effects of
GDF5 on embryonic rat dopaminergic grafts [21, 28].
Initial characterization of the GDF5-overexpressing cell line dem-
onstrated secretion of the mature dimeric form of GDF5 in vitro for at
least 15 days. Treatment of E14 rat VM cultures with conditioned
medium from GDF5-overexpressing CHO cell cultures induced a two-
fold increase in dopaminergic neuronal survival. This treatment had
no effect on the total number of cells or total number of neurons in
these cultures, indicating that the effects of GDF5 were specific to
dopaminergic neurons. Importantly, this experiment proved that the
GDF5 protein that was secreted from the engineered CHO cells was
biologically active, and had protective effects on cultured dopaminer-
gic neurons that had been predicted based on previous studies using
recombinant GDF5 protein [20].
A
B
C
D
E
F
Fig. 3 Neuroprotective and neurorestor-
ative effects of GDF5-CHO cells in two
adult rat models of PD. (A) Outline of
experiment to analyse the neuroprotective
effect of GDF5-CHO cells in the 6-OHDA
MFB lesion model of PD. (B) Amphet-
amine-induced rotational rates at 21 days
post-surgery for each treatment group
(n = 5 per group). (C) Survival of dopami-
nergic neurons in the SN at 28 days
post-surgery expressed as the number of
TH-positive neurons in the left SN as a
percentage of those in the right. Data are
expressed as mean ± SEM. ***P < 0.001
compared with control (lesion only) and
mock-CHO groups, ANOVA with post-hoc
Tukey’s test. (D) Outline of experiment to
analyse the neurorestorative effect of
GDF5-CHO cells in the 6-OHDA striatal
lesion model of PD. (E) Amphetamine-
induced rotational rates at 28 days post-
surgery for each treatment group (n = 5
per group). (F) Survival of dopaminergic
neurons in the SN at 35 days post-sur-
gery, expressed as the number of TH-
positive neurons in the left SN as a per-
centage of those in the right. Data are
expressed as mean ± SEM. *P < 0.05
compared with control (lesion only),
mock-CHO (SN) and mock-CHO (striatum)
groups; ANOVA with post-hoc Tukey’s test.
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The next part of the study examined the feasibility of intrastriatal
implantation of the CHO cell line into the striata of adult rats. As the
CHO cells are effectively xenografts, initially a strategy to control the
host immune response to the implanted cells was conducted. Consid-
eration of the host immune response to grafts is pertinent to all stud-
ies on embryonic tissue transplantation in PD patients. In clinical
studies, patients are routinely administered oral cyclosporine for at
least 6 months following intraputaminal grafting of human foetal VM
tissue. However, a host immune response to such allografts has been
described, even in immunosuppressed patients, comprising the pres-
ence of several immune cell markers within the graft site upon post-
mortem analysis [34]. Although the grafted dopaminergic cells
appeared to be healthy in these patients, the presence of such an
immune response may present a threat to the long-term viability and
functioning of the grafts. The host immune response in adult rats
after intrastriatal transplantation of allogenic neural tissue has previ-
ously been described [32]. The present study used the scoring mech-
anism described by Duan et al. [32] to compare the host immune
response with intrastriatal grafting of the CHO cell line, in rats that
had been treated with oral cyclosporine and in control rats. These
responses were also compared with that to E14 rat VM allografts, the
standard type of graft used in rat models of PD. The immune
response, measured in terms of the intensity of immunostaining for
CD 4, CD 8, MHC I, MHC II, IgM and Ed 1, was significantly higher in
the striata of rats that had received CHO cell grafts alone than in those
that had received CHO cell grafts and oral cyclosporin. In general, the
immune response was greatest after 5 and 10 days and tended to
decrease by 21 and 42 days; this decrease was most pronounced in
the immunosuppressed animals. The host response to E14 VM allo-
grafts (in rats that had not received cyclosporin) was generally the
same magnitude as that to CHO cells with cyclosporin, although in
some cases it was larger, especially at the later time-points. This
study showed the value of immunosuppression for decreasing the
likelihood of host-derived rejection of CHO cell transplants, and thus
all animals were administered oral cyclosporin in the following experi-
ments.
Having established a need for immunosuppression, subsequent
in vivo experiments showed that secretion of the mature dimeric form
of GDF5 by the GDF5-CHO cell line could be achieved for at least
1 week in vivo following transplantation to the striatum of cyclospo-
rin-treated adult rats. In the context of the adult rat models of PD
A
B
C
D E Fig. 4 GDF5-CHO cells improve the survival and function of grafts of
E14 rat VM in an adult rat model of PD. (A) Outline of experiment to
analyse the effects of co-grafting GDF5-CHO cells with E14 rat VM
grafts in the 6-OHDA MFB lesion model of PD. (B) Amphetamine-
induced rotational rates at 3 weeks after lesion surgery and at 1, 2, 3
and 6 weeks post-grafting surgery for each treatment group (n = 5 per
group). (C) Representative photomicrographs of grafted TH-positive
neurons in the ‘graft alone’, ‘graft + GDF5’, ‘graft + GDF5-CHO without
CyA’ and ‘graft + GDF5-CHO with CyA’ groups at 7 weeks post-grafting.
(D) Survival of grafted dopaminergic neurons (expressed as a percent-
age of the total number grafted) at 7 weeks post-grafting in each treat-
ment group (n = 5 per group). Data are expressed as mean ± SEM.
(**P < 0.01, ***P < 0.001 versus control (‘graft alone’), GDF5-CHO
without CyA, mock-CHO with or without CyA groups; ANOVA with post-
hoc Tukey’s test). (E) Representative line drawings showing individual
TH-positive neurons in control (‘graft alone’) and treated ‘graft + GDF5-
CHO with CyA’ grafts. Scale bar = 100 lm.
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used in this study, GDF5 delivery for 1 week should be sufficient to
achieve neuroprotective effects on the lesioned or degenerating nigro-
striatal system.
Two sets of in vivo experiments were performed to evaluate the
effects of the GDF5-overexpressing CHO cell line in adult rat models of
PD. The first showed that implantation of GDF5-CHO cells could signifi-
cantly decrease the neurodegeneration induced by a complete 6-OHDA
lesion of the MFB. The 6-OHDAMFB lesion is an acute neurotoxic insult
leading to the very rapid death of midbrain dopaminergic neurons.
Lesion-induced motor asymmetry and loss of nigral dopaminergic
neurons were both prevented by simultaneous implantation of the
GDF5-overexpressing cell line into the ipsilateral striatum. These data
demonstrate that sustained delivery of GDF5 in vivo can prevent the
loss of dopaminergic neurons in the 6-OHDA MFBmodel of PD.
The second experiment used the ‘partial lesion’ model of PD,
which involves 6-OHDA administration to the dopaminergic terminals
in the adult rat striatum. This induces rapid degeneration of striatal
dopaminergic fibres, followed by the protracted death of their nigral
cell bodies, which begins after a delay of about a week and progresses
over several weeks [35–39]. Thus, this subacute neurotoxic insult
leads to the slower, more protracted death of dopaminergic neurons
than that observed in the MFB lesion model, and is a better model of
the progressive nature of the neurodegeneration that occurs in PD.
Implantation of the GDF5-CHO cells at 1 week after the lesion allowed
the protective effects of this intervention to be assessed at a time,
when the degeneration was still ongoing. As shown above, these cells
were capable of delivering GDF5 in vivo for at least a week after
implantation. Implantation of the GDF5-overexpressing cells into
either the striatum or midbrain, ipsilateral to the lesion, resulted in sig-
nificant improvements in rotational behavioural performance, an indi-
cator of striatal dopaminergic terminal integrity, and in survival of
nigral dopaminergic cell bodies. This shows that in a situation where
midbrain dopaminergic neurons are undergoing progressive cell
death, sustained delivery of GDF5 in vivo to either the striatum or SN
can protect these neurons from the ongoing degeneration. The more
pronounced effect of CHO-GDF5 cells on nigral cell survival in the
MFB lesion study compared with that in the striatal lesion study likely
reflects the fact that the former is a neuroprotective treatment (applied
at time of lesion), whereas the latter induces ameliorative effects on
an already-degenerating nigrostriatal system (applied after lesion).
Recent studies have used cells, such as neural progenitor cells
[40, 41] and bone marrow stromal cells [42], to overexpress the
related neurotrophic factor, GDNF, in rat models of PD. Akerud et al.
reported that transplanted GDNF-overexpressing neural stem cells
survived well in the 6-OHDA-lesioned mouse striatum, expressed high
levels of GDNF for at least 4 months, and had protective effects on
the host nigral dopaminergic neurons [40]. Another study found that
GDNF-expressing human neural progenitor cells could survive and
release GDNF for at least 8 weeks after transplantation into 6-OHDA-
lesioned rats and aged monkeys [41]. That study showed behavioural
improvements in the parkinsonian rats, and a strong trend towards
functional improvements in the aged monkeys. A more recent study
reported neuroprotective effects of GDNF-expressing bone marrow
stromal cells after intrastriatal transplantation in a lactacystin-treated
mouse model of PD [42]. The present study has shown cell survival
and functional effects which compare well with these previous stud-
ies. However, the use of cell lines, such as the CHO line, is not opti-
mal because of the need for immunosuppressive treatment of the
host. More appropriate cell types for sustained GDF5 delivery, such
as embryonic and neural stem cells, are now under investigation in
our laboratory. Nevertheless, the current study supports the proposed
application of GDF5 in PD therapy and paves the way for the develop-
ment of safer mechanisms for the sustained delivery of this neuro-
trophic factor to the parkinsonian brain.
The final study focused on evaluating the effects of intrastriatal
co-implantation of GDF5-overexpressing CHO cells with embryonic
rat VM cells, in rats with MFB lesions. A previous study involved the
co-transplantation of primary foetal grafts and GDNF-producing neur-
ospheres, prepared from embryonic rat striatum, into adult rats that
had MFB 6-OHDA lesions [43]. That study found that the survival of
the foetal grafts was enhanced by co-implantation of the GDNF-pro-
ducing neurospheres, but that this was not reflected by any behavio-
ural recovery in the animals. The authors attributed the lack of
behavioural effects to either down-regulation of the transgene expres-
sion over time or death of the transplanted cells. In the present study,
significant improvements in amphetamine-induced rotational behav-
iour was observed in all rats that had received a control graft, a GDF-
treated graft or a CyA-treated graft co-implanted with GDF-CHO cells,
whereas no changes were seen in the rats that had received co-
implants without CyA. This shows that in the rats which were treated
with CyA, the GDF5-overexpressing cells survived well and did not
induce any detrimental effects on the grafted VM cells. However,
there was no difference in the degree of reversal of amphetamine-
induced rotational asymmetry between the groups that had received
untreated grafts, GDF5-treated grafts and GDF5-CHO-co-implanted
grafts. This probably reflects the fact that there were enough surviv-
ing dopaminergic neurons in each of these grafts at the 6-week time-
point to ensure almost complete reversal of rotational asymmetry.
Post-mortem immunohistochemistry showed that each of the rats in
these three groups had more than 4000 surviving dopaminergic neu-
rons. It has been shown that ~2000 transplanted dopaminergic neu-
rons can achieve a 50% reduction in amphetamine-induced rotations
[44]. In animals that had been treated with cyclosporine, VM grafts
that were co-implanted with GDF5-CHO cells were found to have sig-
nificantly more dopaminergic neurons than control VM grafts or those
that were co-implanted with mock-CHO cells. In fact, the dopaminer-
gic neuronal survival in GDF5-CHO treated grafts was equivalent to
that in VM grafts that had been treated with a high dose (50 lg) of
recombinant human GDF5. In addition, upon post-mortem examina-
tion, the dopaminergic neurons within these treated grafts were more
mature than those in control grafts, displaying longer neurites and
more branching. An effect of GDF5 on dopaminergic neuronal mor-
phological development has been previously shown [20–22] and may
be critically important for the use of this factor in grafting strategies,
where the successful integration of the transplanted dopaminergic
neurons into the host striatal neuronal circuitry is necessary to confer
functional effects. Transplantation of embryonic dopaminergic neu-
rons or those derived from other sources, such as stem cells,
remains a viable option for the treatment of PD [7, 45]. The success
of this approach will ultimately be determined by the survival of the
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transplanted cells and their integration into the host brain paren-
chyma. The current data show that sustained delivery of GDF5 in vivo
increases the survival of transplanted dopaminergic neurons and
improves their morphological development, which may promote their
functional integration into the host striatum.
Two of the most promising strategies for the future therapy for
PD are the delivery of neurotrophic factors to protect degenerating
dopaminergic neurons, and the use of embryonic dopaminergic neu-
rons or those derived from other sources, such as stem cells, to
replace the lost dopaminergic neurons. The current study has shown
that overexpression of the neurotrophic factor, GDF5, has protective
effects on the degenerating adult rat nigrostriatal system and sur-
vival-promoting effects on transplanted embryonic rat dopaminergic
neurons in an in vivo rat model of PD. The use of xenogenic cell lines,
such as CHO cells, is not feasible for clinical application because of
immunogenic concerns and the risk of tumour formation. Thus, the
development of safer methods of delivering neurotrophic factors in
appropriate doses to the degenerating nigrostriatal dopaminergic
system is paramount to the future successful clinical application of
neuroprotective therapies for PD. In conclusion, this study has pro-
vided proof-of-principle that sustained delivery of GDF5 in vivo can
confer neuroprotective effects in PD models, and it paves the way for
the development of efficient, targetted and safe delivery methods.
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